Dataset Information

Proteomic analysis of hippocampus in relation to effects of yokukansan on diabetic model mice showing dementia

ABSTRACT: Diabetes is at an increased risk for development of dementia and effective treatments for diabetes-induced dementia are required with urgency. Yokukansan, a Kampo medicine, is used clinically to treat several neurological conditions including dementia. In this study, we aimed to show the effects of yokukansan on learning and memory functions in diabetes-induced dementia and to clarify the molecular mechanisms inducing the effects in the hippocampus of yokukansan- and non-treated diabetic model mice. Morris water maze test showed that yokukansan admin-istration significantly improved learning and memory functions of diabetic model mice. In the proteomic analysis, significant changes in expression of 10 (4 up- and 6 down-regulated) proteins and 8 (3 up- and 5 down-regulated) phosphoproteins were observed in the hippocampus of yokukansan-treated diabetic model mice. These identified proteins and phosphoproteins could be functionally classified as neuronal development, cellular cytoskeleton, energy metabolism, oxi-doreductase, protein deubiquitination, proton transport, and chaperone. Additionally, western blotting validated the changes in CAPZB, tubulin beta-5 chain, and LDHB. Taken together, these results showed that yokukansan improved learning and memory functions in mice with diabe-tes-induced dementia, underlying the changed expression of proteins and phosphoproteins in the hippocampus. We propose that yokukansan could be effective for care of diabetes-induced de-mentia.

ORGANISM(S): Mus Musculus (mouse)

SUBMITTER: Shogo Matsuyama

PROVIDER: PXD027285 | JPOST Repository | Thu Jul 14 00:00:00 BST 2022

REPOSITORIES: jPOST

ACCESS DATA

Similar Datasets

Project description:There has been an incresing body of epidemiologic and biochemical evidence implying the role of cerebral insulin resistance in Alzheimer-type dementia. For a better understanding of the insulin effect on the central nervous system we performed microarray-based gene expression profiling in the hippocampus, striatum and prefrontal cortex of streptozotocin-induced and spontaneously diabetic Goto-Kakizaki rats as model animals for type 1 and type 2 diabetes, respectively. Following pathway analysis and validation of gene lists by RT-PCR, 30 genes from hippocampus, such as the inhibitory neuropeptide galanin, synuclein gamma and uncoupling protein 2, and 22 genes from the prefrontal cortex, e.g. galanin receptor 2, protein kinase gamma and epsilon, ABCA1, CD47 and the RET protooncogene, were found to exhibit altered expression levels in type 2 diabetic model animals in comparison to non-diabetic control animals. These gene lists proved to be partly overlapping and encompassed genes related to neurotransmission, lipidmetabolism, neuronal development, insulin secretion, oxidative damage and DNA repair. On the other hand, no significant alterations were found in the transcriptomes of the corpus sriatum in the same animals. Changes in the cerebral gene expression profiles seemed to be specific for the type 2 diabetic model, as no such alterations were found in streptozotocin-treated animals. According to our knowledge this is the first characterization of the whole-genome expression changes of specific brain regions in a diabetic model. Our findings shed light on the complex role of insulin signaling in fine-tuning brain functions, and provide further experimental evidence in support of the recently elaborated theory of type 3diabetes. Experiments were performed with 9 animals from each group. Wistar rats (control), streptoztocin-treated Wistar rats (type 1 diabetes) and Goto-Kakizaki rats (type 2 diabetes). The brain was removed and the striatum, hippocampus and prefrontal cortex were dissected. Samples from 3-3 identically treated animals were pooled. That means, 3 biological parallels were prepared from each brain region of type 1 or type 2 diabetic and control animals, amounting to a total of 27 different pooled samples.

Project description:We demonstrate diverse roles of interferonâgamma (IFN-Î³) in the induction and regulation of immune-mediated inflammation using a transfer model of autoimmune diabetes. The diabetogenic CD4+BDC2.5 (BDC) T cell clone upon transfer into NOD.scid mice induced destruction of islets of Langerhans leading to diabetes. Administration of a neutralizing antibody to IFN-Î³ (H22) resulted in long term protection (LTP) from diabetes, with inflammation but persistence of a significant, albeit decreased numbers of Î²-cells. BDC T cells were a mixture of cells expressing high, intermediate and low levels of the T cell receptor. Clonotype-low BDC T cells were required for LTP. Furthermore, islet infiltrating leukocytes in the LTP mice contained Foxp3+CD4 T cells. Islet inflammation in both diabetic and LTP mice was characterized by heavy infiltration of macrophages. Gene expression profiles indicated that macrophages in diabetic mice were M1-type, while LTP mice contained M2-differentiated. The LTP was abolished if mice were treated with either an antibody depleting CD4 T cells, or a neutralizing antibody to CTLA-4, in this case, only at a late stage. Neutralization of IL-10, TGF-Î², GITR or CD25 had no effect. Transfer of only clonotype-high expressing BDC T cells induced diabetes but in contrast, H22 antibodies did not inhibit diabetes. While clonotype high T cells induced diabetes even when IFN-Î³ was neutralized, paradoxically, there was reduced inflammation and no diabetes if host myeloid cells lacked IFN-Î³ receptor. Hence, using monoclonal CD4 T cells, IFN-Î³ can have a wide diversity of roles, depending on the setting of the immune process. Experiment Overall Design: Pancreatic islets were laser-capture microdissected from mice injected with diabetogenic T cells. One cohort of mice also received injections with anti-interfereon gamma monoclonal antibody, which protected those mice from developing diabetes. RNA prepared from islets was amplified and analyzed by Affymetrix GeneChips. Each GeneChip was prepared from RNA pooled from 5 mice at each timepoint. GeneChips were prepared from RNA extracted at different days following injection of T cells. The following days were assayed day 0 (i.e., untreated), day 3 (for diabetic and protected islets), day 4 (diabetic and protected), day 5 (only for protected, as diabetic islets were too edematous to dissect), day 8 (diabetic and protected).

Dataset Information

Proteomic analysis of hippocampus in relation to effects of yokukansan on diabetic model mice showing dementia

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure